# HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

> **NCT05373264** · PHASE3 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 300 (estimated)

## Conditions studied

- ADPKD

## Interventions

- **DRUG:** Hydrochlorothiazide 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05373264
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2030-07
- **Final completion:** 2031-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373264, "HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05373264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*